nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—SLCO1B3—Conjugated Estrogens—osteoporosis	0.165	0.239	CbGbCtD
Olmesartan—SLCO1B3—Estradiol—osteoporosis	0.145	0.21	CbGbCtD
Olmesartan—ABCC2—Ethinyl Estradiol—osteoporosis	0.115	0.167	CbGbCtD
Olmesartan—SLCO1B1—Conjugated Estrogens—osteoporosis	0.0964	0.139	CbGbCtD
Olmesartan—ABCC2—Conjugated Estrogens—osteoporosis	0.0847	0.122	CbGbCtD
Olmesartan—SLCO1B1—Estradiol—osteoporosis	0.0846	0.122	CbGbCtD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00562	0.152	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00527	0.143	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—REN—osteoporosis	0.00297	0.0804	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—ACE—osteoporosis	0.00185	0.0502	CbGpPWpGaD
Olmesartan—SLCO1B3—Bile acid and bile salt metabolism—CYP27A1—osteoporosis	0.0015	0.0406	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—TUBA1B—osteoporosis	0.00129	0.0348	CbGpPWpGaD
Olmesartan—SLCO1B1—Bile acid and bile salt metabolism—CYP27A1—osteoporosis	0.00101	0.0273	CbGpPWpGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000897	0.0243	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000843	0.0228	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—MGLL—osteoporosis	0.000575	0.0156	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—TGFB1—osteoporosis	0.00057	0.0154	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000515	0.014	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.000514	0.0139	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CALCR—osteoporosis	0.000365	0.0099	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—PTH1R—osteoporosis	0.000365	0.0099	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000287	0.00777	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000286	0.00776	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000272	0.00737	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000245	0.00665	CbGpPWpGaD
Olmesartan—Loss of consciousness—Zoledronate—osteoporosis	0.000229	0.000846	CcSEcCtD
Olmesartan—Pharyngitis—Estradiol—osteoporosis	0.000229	0.000846	CcSEcCtD
Olmesartan—Nervous system disorder—Pamidronate—osteoporosis	0.000229	0.000844	CcSEcCtD
Olmesartan—Thrombocytopenia—Pamidronate—osteoporosis	0.000228	0.000842	CcSEcCtD
Olmesartan—Urinary tract disorder—Estradiol—osteoporosis	0.000228	0.000842	CcSEcCtD
Olmesartan—Vomiting—Etidronic acid—osteoporosis	0.000228	0.000841	CcSEcCtD
Olmesartan—Cough—Zoledronate—osteoporosis	0.000228	0.00084	CcSEcCtD
Olmesartan—Oedema peripheral—Estradiol—osteoporosis	0.000228	0.00084	CcSEcCtD
Olmesartan—Tachycardia—Pamidronate—osteoporosis	0.000228	0.00084	CcSEcCtD
Olmesartan—Connective tissue disorder—Estradiol—osteoporosis	0.000227	0.000837	CcSEcCtD
Olmesartan—Urethral disorder—Estradiol—osteoporosis	0.000227	0.000835	CcSEcCtD
Olmesartan—Rash—Etidronic acid—osteoporosis	0.000226	0.000834	CcSEcCtD
Olmesartan—Dermatitis—Etidronic acid—osteoporosis	0.000226	0.000834	CcSEcCtD
Olmesartan—Vertigo—Conjugated Estrogens—osteoporosis	0.000226	0.000833	CcSEcCtD
Olmesartan—Hyperhidrosis—Pamidronate—osteoporosis	0.000225	0.000832	CcSEcCtD
Olmesartan—Syncope—Conjugated Estrogens—osteoporosis	0.000225	0.000831	CcSEcCtD
Olmesartan—Headache—Etidronic acid—osteoporosis	0.000225	0.000829	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—osteoporosis	0.000224	0.00609	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000224	0.000824	CcSEcCtD
Olmesartan—Asthenia—Estropipate—osteoporosis	0.000223	0.000821	CcSEcCtD
Olmesartan—Anorexia—Pamidronate—osteoporosis	0.000222	0.00082	CcSEcCtD
Olmesartan—Myalgia—Zoledronate—osteoporosis	0.000222	0.00082	CcSEcCtD
Olmesartan—Arthralgia—Zoledronate—osteoporosis	0.000222	0.00082	CcSEcCtD
Olmesartan—Chest pain—Zoledronate—osteoporosis	0.000222	0.00082	CcSEcCtD
Olmesartan—Palpitations—Conjugated Estrogens—osteoporosis	0.000222	0.000819	CcSEcCtD
Olmesartan—Insomnia—Risedronate—osteoporosis	0.000222	0.000818	CcSEcCtD
Olmesartan—Anxiety—Zoledronate—osteoporosis	0.000221	0.000817	CcSEcCtD
Olmesartan—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000221	0.000815	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000221	0.000814	CcSEcCtD
Olmesartan—Pruritus—Estropipate—osteoporosis	0.00022	0.00081	CcSEcCtD
Olmesartan—Discomfort—Zoledronate—osteoporosis	0.00022	0.00081	CcSEcCtD
Olmesartan—Asthenia—Alendronate—osteoporosis	0.000219	0.000809	CcSEcCtD
Olmesartan—Cough—Conjugated Estrogens—osteoporosis	0.000219	0.000809	CcSEcCtD
Olmesartan—Hypotension—Pamidronate—osteoporosis	0.000218	0.000804	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000217	0.000801	CcSEcCtD
Olmesartan—Fatigue—Ethinyl Estradiol—osteoporosis	0.000217	0.0008	CcSEcCtD
Olmesartan—Pruritus—Alendronate—osteoporosis	0.000216	0.000798	CcSEcCtD
Olmesartan—Dyspepsia—Risedronate—osteoporosis	0.000216	0.000797	CcSEcCtD
Olmesartan—Constipation—Ethinyl Estradiol—osteoporosis	0.000215	0.000794	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—IL1B—osteoporosis	0.000215	0.00582	CbGpPWpGaD
Olmesartan—Chest pain—Conjugated Estrogens—osteoporosis	0.000214	0.000789	CcSEcCtD
Olmesartan—Arthralgia—Conjugated Estrogens—osteoporosis	0.000214	0.000789	CcSEcCtD
Olmesartan—Myalgia—Conjugated Estrogens—osteoporosis	0.000214	0.000789	CcSEcCtD
Olmesartan—Asthenia—Ibandronate—osteoporosis	0.000214	0.000788	CcSEcCtD
Olmesartan—Anxiety—Conjugated Estrogens—osteoporosis	0.000213	0.000786	CcSEcCtD
Olmesartan—Nausea—Etidronic acid—osteoporosis	0.000213	0.000786	CcSEcCtD
Olmesartan—Anaphylactic shock—Zoledronate—osteoporosis	0.000213	0.000786	CcSEcCtD
Olmesartan—Oedema—Zoledronate—osteoporosis	0.000213	0.000786	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000213	0.000784	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000212	0.000784	CcSEcCtD
Olmesartan—Diarrhoea—Estropipate—osteoporosis	0.000212	0.000783	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Risedronate—osteoporosis	0.000212	0.000781	CcSEcCtD
Olmesartan—Infection—Zoledronate—osteoporosis	0.000212	0.000781	CcSEcCtD
Olmesartan—Fatigue—Risedronate—osteoporosis	0.000212	0.00078	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000211	0.00573	CbGpPWpGaD
Olmesartan—Insomnia—Pamidronate—osteoporosis	0.000211	0.000778	CcSEcCtD
Olmesartan—Pruritus—Ibandronate—osteoporosis	0.000211	0.000777	CcSEcCtD
Olmesartan—Pain—Risedronate—osteoporosis	0.00021	0.000774	CcSEcCtD
Olmesartan—Constipation—Risedronate—osteoporosis	0.00021	0.000774	CcSEcCtD
Olmesartan—Angiopathy—Estradiol—osteoporosis	0.00021	0.000773	CcSEcCtD
Olmesartan—Shock—Zoledronate—osteoporosis	0.00021	0.000773	CcSEcCtD
Olmesartan—Diarrhoea—Alendronate—osteoporosis	0.000209	0.000772	CcSEcCtD
Olmesartan—Asthenia—Calcitriol—osteoporosis	0.000209	0.000771	CcSEcCtD
Olmesartan—Nervous system disorder—Zoledronate—osteoporosis	0.000209	0.000771	CcSEcCtD
Olmesartan—Thrombocytopenia—Zoledronate—osteoporosis	0.000209	0.000769	CcSEcCtD
Olmesartan—Mediastinal disorder—Estradiol—osteoporosis	0.000208	0.000768	CcSEcCtD
Olmesartan—Tachycardia—Zoledronate—osteoporosis	0.000208	0.000767	CcSEcCtD
Olmesartan—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000207	0.000765	CcSEcCtD
Olmesartan—Skin disorder—Zoledronate—osteoporosis	0.000207	0.000763	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CALCR—osteoporosis	0.000206	0.00559	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PTH1R—osteoporosis	0.000206	0.00559	CbGpPWpGaD
Olmesartan—Pruritus—Calcitriol—osteoporosis	0.000206	0.00076	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000206	0.00558	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Zoledronate—osteoporosis	0.000206	0.00076	CcSEcCtD
Olmesartan—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000206	0.000759	CcSEcCtD
Olmesartan—Diarrhoea—Raloxifene—osteoporosis	0.000206	0.000759	CcSEcCtD
Olmesartan—Dyspepsia—Pamidronate—osteoporosis	0.000205	0.000757	CcSEcCtD
Olmesartan—Dizziness—Estropipate—osteoporosis	0.000205	0.000757	CcSEcCtD
Olmesartan—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000205	0.000757	CcSEcCtD
Olmesartan—Oedema—Conjugated Estrogens—osteoporosis	0.000205	0.000757	CcSEcCtD
Olmesartan—Alopecia—Estradiol—osteoporosis	0.000204	0.000753	CcSEcCtD
Olmesartan—Infection—Conjugated Estrogens—osteoporosis	0.000204	0.000752	CcSEcCtD
Olmesartan—Diarrhoea—Ibandronate—osteoporosis	0.000204	0.000751	CcSEcCtD
Olmesartan—Anorexia—Zoledronate—osteoporosis	0.000203	0.000749	CcSEcCtD
Olmesartan—Decreased appetite—Pamidronate—osteoporosis	0.000203	0.000748	CcSEcCtD
Olmesartan—Mental disorder—Estradiol—osteoporosis	0.000202	0.000747	CcSEcCtD
Olmesartan—Dizziness—Alendronate—osteoporosis	0.000202	0.000746	CcSEcCtD
Olmesartan—Shock—Conjugated Estrogens—osteoporosis	0.000202	0.000744	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000201	0.000743	CcSEcCtD
Olmesartan—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000201	0.000742	CcSEcCtD
Olmesartan—Malnutrition—Estradiol—osteoporosis	0.000201	0.000742	CcSEcCtD
Olmesartan—Fatigue—Pamidronate—osteoporosis	0.000201	0.000742	CcSEcCtD
Olmesartan—Gastrointestinal pain—Risedronate—osteoporosis	0.000201	0.00074	CcSEcCtD
Olmesartan—Tachycardia—Conjugated Estrogens—osteoporosis	0.0002	0.000738	CcSEcCtD
Olmesartan—Urticaria—Ethinyl Estradiol—osteoporosis	0.0002	0.000737	CcSEcCtD
Olmesartan—Constipation—Pamidronate—osteoporosis	0.000199	0.000736	CcSEcCtD
Olmesartan—Pain—Pamidronate—osteoporosis	0.000199	0.000736	CcSEcCtD
Olmesartan—Diarrhoea—Calcitriol—osteoporosis	0.000199	0.000735	CcSEcCtD
Olmesartan—Skin disorder—Conjugated Estrogens—osteoporosis	0.000199	0.000735	CcSEcCtD
Olmesartan—Hypotension—Zoledronate—osteoporosis	0.000199	0.000734	CcSEcCtD
Olmesartan—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000199	0.000734	CcSEcCtD
Olmesartan—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000199	0.000734	CcSEcCtD
Olmesartan—Dizziness—Raloxifene—osteoporosis	0.000199	0.000733	CcSEcCtD
Olmesartan—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000198	0.000731	CcSEcCtD
Olmesartan—Vomiting—Estropipate—osteoporosis	0.000197	0.000728	CcSEcCtD
Olmesartan—Dizziness—Ibandronate—osteoporosis	0.000197	0.000726	CcSEcCtD
Olmesartan—Rash—Estropipate—osteoporosis	0.000196	0.000722	CcSEcCtD
Olmesartan—Dermatitis—Estropipate—osteoporosis	0.000196	0.000721	CcSEcCtD
Olmesartan—Anorexia—Conjugated Estrogens—osteoporosis	0.000196	0.000721	CcSEcCtD
Olmesartan—Urticaria—Risedronate—osteoporosis	0.000195	0.000719	CcSEcCtD
Olmesartan—Back pain—Estradiol—osteoporosis	0.000195	0.000718	CcSEcCtD
Olmesartan—Headache—Estropipate—osteoporosis	0.000194	0.000717	CcSEcCtD
Olmesartan—Vomiting—Alendronate—osteoporosis	0.000194	0.000717	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000194	0.000716	CcSEcCtD
Olmesartan—Body temperature increased—Risedronate—osteoporosis	0.000194	0.000715	CcSEcCtD
Olmesartan—Abdominal pain—Risedronate—osteoporosis	0.000194	0.000715	CcSEcCtD
Olmesartan—Muscle spasms—Estradiol—osteoporosis	0.000193	0.000713	CcSEcCtD
Olmesartan—Rash—Alendronate—osteoporosis	0.000193	0.000711	CcSEcCtD
Olmesartan—Insomnia—Zoledronate—osteoporosis	0.000193	0.000711	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000193	0.00522	CbGpPWpGaD
Olmesartan—Dermatitis—Alendronate—osteoporosis	0.000193	0.00071	CcSEcCtD
Olmesartan—Feeling abnormal—Pamidronate—osteoporosis	0.000192	0.000709	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—PTH—osteoporosis	0.000192	0.0052	CbGpPWpGaD
Olmesartan—Hypotension—Conjugated Estrogens—osteoporosis	0.000192	0.000707	CcSEcCtD
Olmesartan—Headache—Alendronate—osteoporosis	0.000192	0.000706	CcSEcCtD
Olmesartan—Vomiting—Raloxifene—osteoporosis	0.000191	0.000705	CcSEcCtD
Olmesartan—Gastrointestinal pain—Pamidronate—osteoporosis	0.000191	0.000703	CcSEcCtD
Olmesartan—Rash—Raloxifene—osteoporosis	0.00019	0.000699	CcSEcCtD
Olmesartan—Dermatitis—Raloxifene—osteoporosis	0.000189	0.000699	CcSEcCtD
Olmesartan—Vomiting—Ibandronate—osteoporosis	0.000189	0.000698	CcSEcCtD
Olmesartan—Headache—Raloxifene—osteoporosis	0.000188	0.000695	CcSEcCtD
Olmesartan—Rash—Ibandronate—osteoporosis	0.000188	0.000692	CcSEcCtD
Olmesartan—Dermatitis—Ibandronate—osteoporosis	0.000188	0.000692	CcSEcCtD
Olmesartan—Dyspepsia—Zoledronate—osteoporosis	0.000188	0.000692	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—PTH1R—osteoporosis	0.000187	0.00508	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CALCR—osteoporosis	0.000187	0.00508	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000187	0.000689	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CNR2—osteoporosis	0.000187	0.00507	CbGpPWpGaD
Olmesartan—Ill-defined disorder—Estradiol—osteoporosis	0.000187	0.000688	CcSEcCtD
Olmesartan—Headache—Ibandronate—osteoporosis	0.000187	0.000688	CcSEcCtD
Olmesartan—Insomnia—Conjugated Estrogens—osteoporosis	0.000186	0.000684	CcSEcCtD
Olmesartan—Vomiting—Calcitriol—osteoporosis	0.000185	0.000683	CcSEcCtD
Olmesartan—Decreased appetite—Zoledronate—osteoporosis	0.000185	0.000683	CcSEcCtD
Olmesartan—Agitation—Estradiol—osteoporosis	0.000185	0.000682	CcSEcCtD
Olmesartan—Nausea—Estropipate—osteoporosis	0.000184	0.00068	CcSEcCtD
Olmesartan—Abdominal pain—Pamidronate—osteoporosis	0.000184	0.00068	CcSEcCtD
Olmesartan—Body temperature increased—Pamidronate—osteoporosis	0.000184	0.00068	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000184	0.000678	CcSEcCtD
Olmesartan—Angioedema—Estradiol—osteoporosis	0.000184	0.000678	CcSEcCtD
Olmesartan—Rash—Calcitriol—osteoporosis	0.000184	0.000678	CcSEcCtD
Olmesartan—Fatigue—Zoledronate—osteoporosis	0.000184	0.000677	CcSEcCtD
Olmesartan—Dermatitis—Calcitriol—osteoporosis	0.000184	0.000677	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000183	0.00495	CbGpPWpGaD
Olmesartan—Headache—Calcitriol—osteoporosis	0.000183	0.000673	CcSEcCtD
Olmesartan—Pain—Zoledronate—osteoporosis	0.000182	0.000672	CcSEcCtD
Olmesartan—Constipation—Zoledronate—osteoporosis	0.000182	0.000672	CcSEcCtD
Olmesartan—Nausea—Alendronate—osteoporosis	0.000182	0.00067	CcSEcCtD
Olmesartan—Malaise—Estradiol—osteoporosis	0.000181	0.000669	CcSEcCtD
Olmesartan—Vertigo—Estradiol—osteoporosis	0.000181	0.000667	CcSEcCtD
Olmesartan—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000181	0.000666	CcSEcCtD
Olmesartan—Asthenia—Ethinyl Estradiol—osteoporosis	0.000181	0.000666	CcSEcCtD
Olmesartan—Syncope—Estradiol—osteoporosis	0.00018	0.000665	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000179	0.00486	CbGpPWpGaD
Olmesartan—Nausea—Raloxifene—osteoporosis	0.000179	0.000659	CcSEcCtD
Olmesartan—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000178	0.000658	CcSEcCtD
Olmesartan—Pruritus—Ethinyl Estradiol—osteoporosis	0.000178	0.000657	CcSEcCtD
Olmesartan—Palpitations—Estradiol—osteoporosis	0.000178	0.000656	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000177	0.000653	CcSEcCtD
Olmesartan—Fatigue—Conjugated Estrogens—osteoporosis	0.000177	0.000652	CcSEcCtD
Olmesartan—Nausea—Ibandronate—osteoporosis	0.000177	0.000652	CcSEcCtD
Olmesartan—Loss of consciousness—Estradiol—osteoporosis	0.000177	0.000652	CcSEcCtD
Olmesartan—Asthenia—Risedronate—osteoporosis	0.000176	0.000649	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—WNT1—osteoporosis	0.000176	0.00476	CbGpPWpGaD
Olmesartan—Feeling abnormal—Zoledronate—osteoporosis	0.000176	0.000647	CcSEcCtD
Olmesartan—Cough—Estradiol—osteoporosis	0.000176	0.000647	CcSEcCtD
Olmesartan—Constipation—Conjugated Estrogens—osteoporosis	0.000175	0.000647	CcSEcCtD
Olmesartan—Pain—Conjugated Estrogens—osteoporosis	0.000175	0.000647	CcSEcCtD
Olmesartan—Gastrointestinal pain—Zoledronate—osteoporosis	0.000174	0.000642	CcSEcCtD
Olmesartan—Pruritus—Risedronate—osteoporosis	0.000174	0.00064	CcSEcCtD
Olmesartan—Nausea—Calcitriol—osteoporosis	0.000173	0.000638	CcSEcCtD
Olmesartan—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000172	0.000635	CcSEcCtD
Olmesartan—Myalgia—Estradiol—osteoporosis	0.000171	0.000632	CcSEcCtD
Olmesartan—Chest pain—Estradiol—osteoporosis	0.000171	0.000632	CcSEcCtD
Olmesartan—Arthralgia—Estradiol—osteoporosis	0.000171	0.000632	CcSEcCtD
Olmesartan—Anxiety—Estradiol—osteoporosis	0.000171	0.000629	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00017	0.000627	CcSEcCtD
Olmesartan—Urticaria—Zoledronate—osteoporosis	0.000169	0.000624	CcSEcCtD
Olmesartan—Discomfort—Estradiol—osteoporosis	0.000169	0.000624	CcSEcCtD
Olmesartan—Abdominal pain—Zoledronate—osteoporosis	0.000168	0.000621	CcSEcCtD
Olmesartan—Body temperature increased—Zoledronate—osteoporosis	0.000168	0.000621	CcSEcCtD
Olmesartan—Diarrhoea—Risedronate—osteoporosis	0.000168	0.000619	CcSEcCtD
Olmesartan—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000168	0.000619	CcSEcCtD
Olmesartan—Asthenia—Pamidronate—osteoporosis	0.000167	0.000617	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—TGFB1—osteoporosis	0.000167	0.00452	CbGpPWpGaD
Olmesartan—Dizziness—Ethinyl Estradiol—osteoporosis	0.000166	0.000614	CcSEcCtD
Olmesartan—Pruritus—Pamidronate—osteoporosis	0.000165	0.000609	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000165	0.00446	CbGpPWpGaD
Olmesartan—Anaphylactic shock—Estradiol—osteoporosis	0.000164	0.000605	CcSEcCtD
Olmesartan—Oedema—Estradiol—osteoporosis	0.000164	0.000605	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—MGLL—osteoporosis	0.000164	0.00444	CbGpPWpGaD
Olmesartan—Infection—Estradiol—osteoporosis	0.000163	0.000602	CcSEcCtD
Olmesartan—Urticaria—Conjugated Estrogens—osteoporosis	0.000163	0.000601	CcSEcCtD
Olmesartan—Dizziness—Risedronate—osteoporosis	0.000162	0.000598	CcSEcCtD
Olmesartan—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000162	0.000598	CcSEcCtD
Olmesartan—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000162	0.000598	CcSEcCtD
Olmesartan—Shock—Estradiol—osteoporosis	0.000162	0.000596	CcSEcCtD
Olmesartan—Nervous system disorder—Estradiol—osteoporosis	0.000161	0.000594	CcSEcCtD
Olmesartan—Tachycardia—Estradiol—osteoporosis	0.00016	0.000591	CcSEcCtD
Olmesartan—Vomiting—Ethinyl Estradiol—osteoporosis	0.00016	0.00059	CcSEcCtD
Olmesartan—Diarrhoea—Pamidronate—osteoporosis	0.00016	0.000589	CcSEcCtD
Olmesartan—Skin disorder—Estradiol—osteoporosis	0.000159	0.000588	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—PTHLH—osteoporosis	0.000159	0.00431	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Estradiol—osteoporosis	0.000159	0.000585	CcSEcCtD
Olmesartan—Rash—Ethinyl Estradiol—osteoporosis	0.000159	0.000585	CcSEcCtD
Olmesartan—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000159	0.000585	CcSEcCtD
Olmesartan—Headache—Ethinyl Estradiol—osteoporosis	0.000158	0.000581	CcSEcCtD
Olmesartan—Vomiting—Risedronate—osteoporosis	0.000156	0.000575	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—TNF—osteoporosis	0.000156	0.00422	CbGpPWpGaD
Olmesartan—Rash—Risedronate—osteoporosis	0.000155	0.000571	CcSEcCtD
Olmesartan—Dermatitis—Risedronate—osteoporosis	0.000155	0.00057	CcSEcCtD
Olmesartan—Dizziness—Pamidronate—osteoporosis	0.000154	0.000569	CcSEcCtD
Olmesartan—Headache—Risedronate—osteoporosis	0.000154	0.000567	CcSEcCtD
Olmesartan—Asthenia—Zoledronate—osteoporosis	0.000153	0.000564	CcSEcCtD
Olmesartan—Pruritus—Zoledronate—osteoporosis	0.000151	0.000556	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—AGER—osteoporosis	0.000151	0.00408	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Estradiol—osteoporosis	0.00015	0.000552	CcSEcCtD
Olmesartan—Nausea—Ethinyl Estradiol—osteoporosis	0.000149	0.000551	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—MGLL—osteoporosis	0.000149	0.00403	CbGpPWpGaD
Olmesartan—Insomnia—Estradiol—osteoporosis	0.000148	0.000548	CcSEcCtD
Olmesartan—Vomiting—Pamidronate—osteoporosis	0.000148	0.000547	CcSEcCtD
Olmesartan—Asthenia—Conjugated Estrogens—osteoporosis	0.000147	0.000543	CcSEcCtD
Olmesartan—Rash—Pamidronate—osteoporosis	0.000147	0.000542	CcSEcCtD
Olmesartan—Dermatitis—Pamidronate—osteoporosis	0.000147	0.000542	CcSEcCtD
Olmesartan—Headache—Pamidronate—osteoporosis	0.000146	0.000539	CcSEcCtD
Olmesartan—Diarrhoea—Zoledronate—osteoporosis	0.000146	0.000538	CcSEcCtD
Olmesartan—Nausea—Risedronate—osteoporosis	0.000146	0.000537	CcSEcCtD
Olmesartan—Pruritus—Conjugated Estrogens—osteoporosis	0.000145	0.000535	CcSEcCtD
Olmesartan—Dyspepsia—Estradiol—osteoporosis	0.000145	0.000533	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—POMC—osteoporosis	0.000143	0.00388	CbGpPWpGaD
Olmesartan—Decreased appetite—Estradiol—osteoporosis	0.000143	0.000526	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000142	0.00385	CbGpPWpGaD
Olmesartan—Gastrointestinal disorder—Estradiol—osteoporosis	0.000142	0.000523	CcSEcCtD
Olmesartan—Fatigue—Estradiol—osteoporosis	0.000142	0.000522	CcSEcCtD
Olmesartan—Dizziness—Zoledronate—osteoporosis	0.000141	0.00052	CcSEcCtD
Olmesartan—Constipation—Estradiol—osteoporosis	0.00014	0.000518	CcSEcCtD
Olmesartan—Pain—Estradiol—osteoporosis	0.00014	0.000518	CcSEcCtD
Olmesartan—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00014	0.000518	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.00014	0.0038	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CALCA—osteoporosis	0.00014	0.00379	CbGpPWpGaD
Olmesartan—Nausea—Pamidronate—osteoporosis	0.000139	0.000511	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000138	0.00375	CbGpPWpGaD
Olmesartan—Dizziness—Conjugated Estrogens—osteoporosis	0.000136	0.0005	CcSEcCtD
Olmesartan—Vomiting—Zoledronate—osteoporosis	0.000135	0.0005	CcSEcCtD
Olmesartan—Feeling abnormal—Estradiol—osteoporosis	0.000135	0.000499	CcSEcCtD
Olmesartan—Rash—Zoledronate—osteoporosis	0.000134	0.000495	CcSEcCtD
Olmesartan—Gastrointestinal pain—Estradiol—osteoporosis	0.000134	0.000495	CcSEcCtD
Olmesartan—Dermatitis—Zoledronate—osteoporosis	0.000134	0.000495	CcSEcCtD
Olmesartan—Headache—Zoledronate—osteoporosis	0.000133	0.000492	CcSEcCtD
Olmesartan—Vomiting—Conjugated Estrogens—osteoporosis	0.00013	0.000481	CcSEcCtD
Olmesartan—Urticaria—Estradiol—osteoporosis	0.00013	0.000481	CcSEcCtD
Olmesartan—Body temperature increased—Estradiol—osteoporosis	0.00013	0.000479	CcSEcCtD
Olmesartan—Abdominal pain—Estradiol—osteoporosis	0.00013	0.000479	CcSEcCtD
Olmesartan—Rash—Conjugated Estrogens—osteoporosis	0.000129	0.000477	CcSEcCtD
Olmesartan—Dermatitis—Conjugated Estrogens—osteoporosis	0.000129	0.000477	CcSEcCtD
Olmesartan—Headache—Conjugated Estrogens—osteoporosis	0.000129	0.000474	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000128	0.00347	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PKM—osteoporosis	0.000128	0.00346	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—FDPS—osteoporosis	0.000128	0.00346	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000127	0.00343	CbGpPWpGaD
Olmesartan—Nausea—Zoledronate—osteoporosis	0.000127	0.000467	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—SOST—osteoporosis	0.000122	0.00332	CbGpPWpGaD
Olmesartan—Nausea—Conjugated Estrogens—osteoporosis	0.000122	0.000449	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—GPD2—osteoporosis	0.000121	0.00328	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PGLS—osteoporosis	0.000121	0.00328	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.00012	0.00326	CbGpPWpGaD
Olmesartan—Asthenia—Estradiol—osteoporosis	0.000118	0.000434	CcSEcCtD
Olmesartan—Pruritus—Estradiol—osteoporosis	0.000116	0.000428	CcSEcCtD
Olmesartan—Diarrhoea—Estradiol—osteoporosis	0.000112	0.000414	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—ATIC—osteoporosis	0.000111	0.003	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PNP—osteoporosis	0.000111	0.003	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTH1R—osteoporosis	0.000111	0.003	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CALCR—osteoporosis	0.000111	0.003	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000111	0.003	CbGpPWpGaD
Olmesartan—Dizziness—Estradiol—osteoporosis	0.000109	0.0004	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—PTH—osteoporosis	0.000108	0.00294	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CNR2—osteoporosis	0.000106	0.00286	CbGpPWpGaD
Olmesartan—Vomiting—Estradiol—osteoporosis	0.000104	0.000385	CcSEcCtD
Olmesartan—Rash—Estradiol—osteoporosis	0.000104	0.000382	CcSEcCtD
Olmesartan—Dermatitis—Estradiol—osteoporosis	0.000103	0.000381	CcSEcCtD
Olmesartan—Headache—Estradiol—osteoporosis	0.000103	0.000379	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—PTH—osteoporosis	9.84e-05	0.00267	CbGpPWpGaD
Olmesartan—Nausea—Estradiol—osteoporosis	9.75e-05	0.00036	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	9.61e-05	0.00261	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CNR2—osteoporosis	9.59e-05	0.0026	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—OXCT1—osteoporosis	9.41e-05	0.00255	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CA2—osteoporosis	9.41e-05	0.00255	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	9.41e-05	0.00255	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—MGLL—osteoporosis	9.17e-05	0.00249	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—WNT1—osteoporosis	9.02e-05	0.00244	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PTHLH—osteoporosis	8.98e-05	0.00243	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MGLL—osteoporosis	8.79e-05	0.00238	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	8.65e-05	0.00235	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LRP5—osteoporosis	8.58e-05	0.00233	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PKM—osteoporosis	8.58e-05	0.00233	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—FDPS—osteoporosis	8.58e-05	0.00233	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LRP6—osteoporosis	8.21e-05	0.00223	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PTHLH—osteoporosis	8.15e-05	0.00221	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GPD2—osteoporosis	8.13e-05	0.0022	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PGLS—osteoporosis	8.13e-05	0.0022	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CALCA—osteoporosis	7.91e-05	0.00214	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—IDH2—osteoporosis	7.8e-05	0.00211	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ATIC—osteoporosis	7.44e-05	0.00202	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PNP—osteoporosis	7.44e-05	0.00202	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP27A1—osteoporosis	7.33e-05	0.00199	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—POMC—osteoporosis	7.32e-05	0.00198	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CALCA—osteoporosis	7.18e-05	0.00195	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ACP5—osteoporosis	7.13e-05	0.00193	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.04e-05	0.00191	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TLN1—osteoporosis	6.93e-05	0.00188	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.72e-05	0.00182	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TPI1—osteoporosis	6.63e-05	0.0018	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—TGFB1—osteoporosis	6.37e-05	0.00173	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—OXCT1—osteoporosis	6.32e-05	0.00171	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CA2—osteoporosis	6.32e-05	0.00171	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—P4HB—osteoporosis	6.24e-05	0.00169	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—MGLL—osteoporosis	6.16e-05	0.00167	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GAPDH—osteoporosis	6.12e-05	0.00166	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—P4HB—osteoporosis	5.98e-05	0.00162	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—RAP1A—osteoporosis	5.96e-05	0.00162	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTH—osteoporosis	5.81e-05	0.00158	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	5.81e-05	0.00158	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RAP1A—osteoporosis	5.71e-05	0.00155	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CNR2—osteoporosis	5.67e-05	0.00154	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	5.64e-05	0.00153	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ADCY5—osteoporosis	5.62e-05	0.00152	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NFATC1—osteoporosis	5.57e-05	0.00151	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—DKK1—osteoporosis	5.53e-05	0.0015	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—WNT1—osteoporosis	5.33e-05	0.00144	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—IDH2—osteoporosis	5.24e-05	0.00142	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.2e-05	0.00141	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FGA—osteoporosis	5.18e-05	0.0014	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ADCY5—osteoporosis	5.11e-05	0.00138	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP27A1—osteoporosis	4.93e-05	0.00134	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ENO1—osteoporosis	4.82e-05	0.00131	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTHLH—osteoporosis	4.82e-05	0.00131	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—BMP2—osteoporosis	4.82e-05	0.00131	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ADCY5—osteoporosis	4.81e-05	0.0013	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ACP5—osteoporosis	4.79e-05	0.0013	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PSMA5—osteoporosis	4.75e-05	0.00129	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PSMA2—osteoporosis	4.75e-05	0.00129	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.73e-05	0.00128	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FGB—osteoporosis	4.71e-05	0.00128	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PSMA2—osteoporosis	4.55e-05	0.00123	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PSMA5—osteoporosis	4.55e-05	0.00123	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ADCY5—osteoporosis	4.52e-05	0.00122	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TPI1—osteoporosis	4.46e-05	0.00121	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CALCA—osteoporosis	4.24e-05	0.00115	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—P4HB—osteoporosis	4.19e-05	0.00114	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—POMC—osteoporosis	4.14e-05	0.00112	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GAPDH—osteoporosis	4.11e-05	0.00111	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—RAP1A—osteoporosis	4.01e-05	0.00109	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP19A1—osteoporosis	3.85e-05	0.00104	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KL—osteoporosis	3.85e-05	0.00104	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—POMC—osteoporosis	3.76e-05	0.00102	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6R—osteoporosis	3.66e-05	0.000993	CbGpPWpGaD
Olmesartan—Losartan—ACE—osteoporosis	3.62e-05	1	CrCbGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.49e-05	0.000947	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ENO1—osteoporosis	3.24e-05	0.000878	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PSMA2—osteoporosis	3.19e-05	0.000865	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PSMA5—osteoporosis	3.19e-05	0.000865	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ADCY5—osteoporosis	3.15e-05	0.000853	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GPX1—osteoporosis	3.14e-05	0.00085	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADCY5—osteoporosis	3.02e-05	0.000818	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SPP1—osteoporosis	2.92e-05	0.000791	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—MTHFR—osteoporosis	2.9e-05	0.000785	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IRS2—osteoporosis	2.64e-05	0.000716	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP19A1—osteoporosis	2.59e-05	0.000702	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LEP—osteoporosis	2.58e-05	0.0007	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ESR1—osteoporosis	2.47e-05	0.000668	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—POMC—osteoporosis	2.32e-05	0.000628	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IRS1—osteoporosis	2.3e-05	0.000625	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—POMC—osteoporosis	2.22e-05	0.000602	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6R—osteoporosis	2.16e-05	0.000587	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IGF1—osteoporosis	2.13e-05	0.000579	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ADCY5—osteoporosis	2.11e-05	0.000573	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GPX1—osteoporosis	2.11e-05	0.000571	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—MTHFR—osteoporosis	1.95e-05	0.000527	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6—osteoporosis	1.63e-05	0.000442	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—POMC—osteoporosis	1.56e-05	0.000422	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—osteoporosis	1.28e-05	0.000348	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFB1—osteoporosis	1.28e-05	0.000347	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6—osteoporosis	9.64e-06	0.000261	CbGpPWpGaD
